sorry, we can't preview this file

Epicardial adipose tissue manuscript 31Mar2021.docx (303.93 kB)

Epicardial adipose tissue in obesity-related cardiac dysfunction.

Download (303.93 kB)
journal contribution
posted on 16.06.2021, 09:36 by Sarah L Ayton, Gaurav S Gulsin, Gerry P McCann, Alastair J Moss
Obesity is associated with the development of heart failure and is a major risk factor for heart failure with preserved ejection fraction (HFpEF). Epicardial adipose tissue (EAT) is a unique visceral fat in close proximity to the heart and is of particular interest to the study of cardiac disease. Small poorly differentiated adipocytes with altered lipid:water content are associated with a proinflammatory secretome and may contribute to the pathophysiology observed in HFpEF. Multimodality imaging approaches can be used to quantify EAT volume and characterise EAT composition. Current research studies remain unclear as to the magnitude of effect that EAT plays on myocardial dysfunction and further work using multimodality imaging techniques is ongoing. Pharmacological interventions, including glucagon-like peptide 1 receptor agonists and sodium-dependent glucose linked transporter 2 inhibitors have shown promise in attenuating the deleterious metabolic and inflammatory changes seen in EAT. Clinical studies are ongoing to explore whether these therapies exert their beneficial effects by modifying this unique adipose deposit.

History

Author affiliation

Department of Cardiovascular Sciences

Version

AM (Accepted Manuscript)

Published in

Heart

Publisher

BMJ

issn

1355-6037

eissn

1468-201X

Acceptance date

22/04/2021

Copyright date

2021

Available date

16/06/2021

Spatial coverage

England

Language

eng

Usage metrics

Categories

Exports